Literature DB >> 2982538

Vascular alpha-adrenoceptors in man: interactions with adrenaline and noradrenaline.

P van Brummelen, K Jie, P Vermey, P B Timmermans, P A van Zwieten.   

Abstract

Adrenaline and noradrenaline were infused in cumulative doses into the brachial artery of six healthy volunteers and changes in forearm blood flow (FBF) were measured by plethysmography. The catecholamines were infused together with saline, yohimbine and doxazosin, in that order. All infusions were given in the presence of intra-arterial propranolol to prevent beta-adrenoceptor-mediated effects. Adrenaline and noradrenaline reduced FBF significantly. This decrease in FBF was significantly attenuated by doxazosin as well as by yohimbine. No differences were found between adrenaline and noradrenaline. It is concluded that postjunctional alpha 1- and alpha 2-adrenoceptors are involved in the vasoconstriction caused by exogenous adrenaline and noradrenaline in man. The relevance of circulating adrenaline for the alpha 2-adrenoceptor-mediated contribution to basal vascular tone remains to be established.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982538     DOI: 10.1042/cs068s151

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

1.  Postjunctional alpha 2-adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels.

Authors:  H Nielsen; S M Thom; A D Hughes; G N Martin; M J Mulvany; P S Sever
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 2.  Drugs interacting with alpha adrenoceptors.

Authors:  P A van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

Review 3.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

4.  Alpha-adrenergic receptors in human blood vessels.

Authors:  P van Brummelen; K Jie; P A van Zwieten
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.